• Client Login
Ozmosi
  • Services
    • BEAM Clinical Trial Data
    • GCT Global Clinical Trials
    • PRYZM Pharma Product Database
    • KRYSTL Industry Scan Reporting
    • LENZ Company Pipeline Summary
    • Specialized Consulting
  • About Us
  • Case Studies
  • Newsroom
  • Contact Us
Select Page
FDA Accelerated Approval,  Breakthrough Therapy, and Fast Track Designations Supercharge Drug Development

FDA Accelerated Approval, Breakthrough Therapy, and Fast Track Designations Supercharge Drug Development

Mar 9, 2023 | Industry Trends

FDA Expedited Drug Development Programs The Food and Drug Administration (FDA) follows an established and lengthy approval process that ensures patients have access to therapeutic agents proven to be safe and effective. The process relies upon a structured framework...
ELI LILLY in the Diabetes Market

ELI LILLY in the Diabetes Market

Nov 16, 2017 | Business, Chronic Disease, Diabetes, Disease Area Trends

For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast-acting analog Humalog® and human insulin Humalin and two premix offerings in analog Humalog® Mix 50/50 and human premix Humalin 75/25. Despite a legacy category, this portfolio...

Novo Nordisk Diabetes Pipeline Analysis

Oct 19, 2017 | Chronic Disease, Diabetes, Disease Area Trends

Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog®  and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1...

Merck Diabetes Pipeline Analysis

Aug 28, 2017 | Business, Data Analytics, Diabetes, Disease Area Trends

Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class....

What do the big players have in store for the Diabetes market in the next 12 months?

Aug 4, 2017 | Chronic Disease, Diabetes, Disease Area Trends

Diabetes is one of the most prevalent diseases in the U.S., afflicting over 29 million people across Type 1 and Type 2 patients, according to the CDC1 and represents over a $50 billion dollar industry2. Pharmaceutical companies are constantly racing to create the next...
« Older Entries

Recent Posts

  • FDA Accelerated Approval, Breakthrough Therapy, and Fast Track Designations Supercharge Drug DevelopmentMarch 9, 2023
  • Using Data to Optimize Clinical Trial RecruitmentJanuary 23, 2023
  • Uncovering New Catalyst Events in the Pharmaceutical and Biotech MarketsNovember 11, 2022
  • New Developments in Alzheimer’s TreatmentOctober 7, 2022
  • The Clinical Trial PowershiftSeptember 19, 2022
  • China Reshaping the Clinical Trial PipelineSeptember 19, 2022
  • Home
  • About Us
  • Services
  • Case Studies
  • Newsroom
  • Contact Us
  • Facebook
  • Twitter
OZMOSI© 2023 | All Rights Reserved | Site by Webtyde